A Phase 4 interventional study of LUM/IVA and Placebo in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 12 sites in 2 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2019-06-17.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing lumacaftor in Cystic Fibrosis — none open to participants now, none under way, none of them phase 3. lumacaftor · Cystic Fibrosis.
Among the 20 studies testing lumacaftor in Cystic Fibrosis, this one is the 10th largest by enrollment, is the only one that started in 2016, is the only one in phase 4, and was the 15th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →None of the 20 studies testing lumacaftor in Cystic Fibrosis is open now. The open studies under Cystic Fibrosis, anywhere →
lumacaftor: first FDA approval 2015 (ORKAMBI), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2016.
This study's enrollment of 70 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 66 across the 20 interventional studies. Of the 20 that completed or were terminated, 15 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 20 have an industry lead sponsor. The 1 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 61st largest by enrollment of the 116 interventional ones that give a count, is one of 15 that started in 2016, is one of 2 in phase 4, and was the 55th registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing lumacaftor in Cystic Fibrosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
This is a Phase 4, randomized, double-blind, placebo-controlled, parallel-group study in subjects aged 12 years and older with CF who are homozygous for the F508del-CFTR mutation. This study is designed to evaluate the effect of LUM/IVA on exercise tolerance in subjects with CF, homozygous for the F508del-CFTR mutation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo matched to LUM/IVA fixed-dose combination tablet orally every 12 hours (q12h) for 24 weeks.
Drug: Placebo
LUM 400 milligram (mg)/IVA 250 mg fixed-dose combination tablet orally q12h for 24 weeks.
Drug: LUM/IVA
Drug pages: Lumacaftor · Ivacaftor
Also known as: Lumacaftor/Ivacaftor
Relative (Percent) Change From Baseline in Maximal Oxygen Consumption (VO2max) During Cardiopulmonary Exercise Testing (CPET) at Week 24
CPET was used to assess change in exercise tolerance, as measured by VO2max.
Time frame: Baseline, Week 24
Relative (Percent) Change From Baseline in Exercise Duration During CPET at Week 24
Exercise duration is defined as the time at the termination of CPET exercise minus the corresponding time when CPET starts for each CPET exercise.
Time frame: Baseline, Week 24
Absolute Change From Baseline in Exercise Duration During CPET at Week 24
Exercise duration is defined as the time at the termination of CPET exercise minus the corresponding time when CPET starts for each CPET exercise.
Time frame: Baseline, Week 24
Absolute Change From Baseline in VO2max During CPET at Week 24
CPET was used to assess change in exercise tolerance, as measured by VO2max.
Time frame: Baseline, Week 24
Absolute Change From Baseline in Oxygen Consumption (VO2) at Anaerobic Threshold at Week 24
Anaerobic threshold was defined as the exercise intensity at which lactate starts to accumulate.
Time frame: Baseline, Week 24
Relative (Percent) Change From Baseline in VO2 at Anaerobic Threshold at Week 24
Anaerobic threshold was defined as the exercise intensity at which lactate starts to accumulate.
Time frame: Baseline, Week 24
Absolute Change From Baseline in Functional VO2 Gain at Week 24
Time frame: Baseline, Week 24
Relative (Percent) Change From Baseline in Functional VO2 Gain at Week 24
Time frame: Baseline, Week 24
Absolute Change From Baseline in Pulmonary Ventilation (VE) Versus Carbon Dioxide Production (VCO2) Slope at Week 24
Time frame: Baseline, Week 24
Relative (Percent) Change From Baseline in Pulmonary Ventilation (VE) Versus Carbon Dioxide Production (VCO2) Slope at Week 24
Time frame: Baseline, Week 24
Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Week 24
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: Baseline, Week 24
Relative (Percent) Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Week 24
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: Baseline, Week 24
Absolute Change From Baseline in Body Mass Index (BMI) at Week 24
BMI was defined as weight in kilograms (kg) divided by height in square meter (m\^2).
Time frame: Baseline, Week 24
Relative (Percent) Change From Baseline in BMI at Week 24
BMI was defined as weight in kg divided by height in m\^2.
Time frame: Baseline, Week 24
Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Week 24
The CFQ-R assessed respiratory symptoms on a scale with scores ranging from 0 to 100; where higher scores indicated fewer symptoms and better health-related quality of life.
Time frame: Baseline, Week 24
Number of Participants in Each Severity Category of Patient Health Questionnaire (PHQ-8)
The PHQ-8 is an eight item self-reported measure of depression. Each item is rated on a scale ranging from 0 (not at all) to 3 (nearly every day). Total score is the sum of individual eight items and ranges from 0 to 24, with higher scores indicating more severe depression symptoms. Total score of 0 to 5 indicates none to minimal depression, 6 to 10 indicates mild depression, 11 to 15 indicates moderate depression, 16 to 20 indicates moderately severe depression and 21 to 24 indicates severe depression.
Time frame: Baseline, Week 24
Number of Participants in Each Severity Category of Generalized Anxiety Disorder (GAD-7) Scores
The GAD-7 is a seven item, self-reported measurement of GAD severity. Each item is rated on a scale ranging from 0 (not at all) to 3 (nearly every day). Total score is the sum of individual seven items and ranges from 0 to 21, with higher scores indicating more severe anxiety symptoms. Total score of 0 to 5 indicates none to minimal anxiety, 6 to 10 indicates mild anxiety, 11 to 15 indicates moderate anxiety, 16 to 21 indicates severe anxiety.
Time frame: Baseline, Week 24
Absolute Change From Baseline in Daily Physical Activity Counts as Determined by Actigraphy at Week 24
Participants were provided with a wrist-worn actigraphy device which continuously collected data about daily physical activity counts.
Time frame: Baseline, Week 24
Relative (Percent) Change From Baseline in Physical Activity as Determined by Actigraphy at Week 24
Participants were provided with a wrist-worn actigraphy device which continuously collected data about daily physical activities.
Time frame: Baseline, Week 24
Absolute Change From Baseline in Duration of Sleep Time at Week 24
Participants were provided with a wrist-worn actigraphy device which continuously collected data about sleep duration and quality.
Time frame: Baseline, Week 24
Relative (Percent) Change From Baseline in Duration of Sleep Time at Week 24
Participants were provided with a wrist-worn actigraphy device which continuously collected data about sleep duration and quality.
Time frame: Baseline, Week 24
Absolute Change From Baseline in Time Above Sedentary Duration at Week 24
Participants were provided with a wrist-worn actigraphy device which continuously collected data about daily activities and sleep duration and quality.
Time frame: Baseline, Week 24
Relative (Percent) Change From Baseline in Time Above Sedentary Duration at Week 24
Participants were provided with a wrist-worn actigraphy device which continuously collected data about daily activities and sleep duration and quality.
Time frame: Baseline, Week 24
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: Day 1 up to Week 28
| Milestone | Placebo | LUM/IVA |
|---|---|---|
| Started | 36 | 34 |
| Completed | 36 | 31 |
| Not completed | 0 | 3 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Noncompliance | 0 | 1 |
CPET was used to assess change in exercise tolerance, as measured by VO2max.
| percent change | Placebo | LUM/IVA |
|---|---|---|
| Relative (Percent) Change From Baseline in Maximal Oxygen Consumption (VO2max) During Cardiopulmonary Exercise Testing (CPET) at Week 24 | -3.5 (-7.7 to 0.8) | -6.6 (-11.3 to -2.0) |
Exercise duration is defined as the time at the termination of CPET exercise minus the corresponding time when CPET starts for each CPET exercise.
| percent change | Placebo | LUM/IVA |
|---|---|---|
| Relative (Percent) Change From Baseline in Exercise Duration During CPET at Week 24 | 0.4 (-3.0 to 3.8) | -2.8 (-6.5 to 1.0) |
Exercise duration is defined as the time at the termination of CPET exercise minus the corresponding time when CPET starts for each CPET exercise.
| seconds | Placebo | LUM/IVA |
|---|---|---|
| Absolute Change From Baseline in Exercise Duration During CPET at Week 24 | -2.1 (-20.0 to 15.9) | -17.4 (-37.2 to 2.4) |
CPET was used to assess change in exercise tolerance, as measured by VO2max.
| milliliter per kilogram per minute | Placebo | LUM/IVA |
|---|---|---|
| Absolute Change From Baseline in VO2max During CPET at Week 24 | -1.3 (-2.5 to -0.1) | -2.7 (-4.0 to -1.3) |
Anaerobic threshold was defined as the exercise intensity at which lactate starts to accumulate.
| milliliter per minute | Placebo | LUM/IVA |
|---|---|---|
| Absolute Change From Baseline in Oxygen Consumption (VO2) at Anaerobic Threshold at Week 24 | 94.6 (-5.8 to 195.0) | -55.1 (-168.0 to 57.9) |
Anaerobic threshold was defined as the exercise intensity at which lactate starts to accumulate.
| percent change | Placebo | LUM/IVA |
|---|---|---|
| Relative (Percent) Change From Baseline in VO2 at Anaerobic Threshold at Week 24 | 9.4 (0.9 to 17.8) | 1.8 (-7.7 to 11.3) |
| milliliter per minute per watt | Placebo | LUM/IVA |
|---|---|---|
| Absolute Change From Baseline in Functional VO2 Gain at Week 24 | 0.07 (-0.29 to 0.43) | -0.53 (-0.93 to -0.14) |
| percent change | Placebo | LUM/IVA |
|---|---|---|
| Relative (Percent) Change From Baseline in Functional VO2 Gain at Week 24 | 1.46 (-3.10 to 6.03) | -4.85 (-9.93 to 0.22) |
| ratio | Placebo | LUM/IVA |
|---|---|---|
| Absolute Change From Baseline in Pulmonary Ventilation (VE) Versus Carbon Dioxide Production (VCO2) Slope at Week 24 | 0.5 (-0.3 to 1.4) | 0.8 (-0.1 to 1.7) |
| percent change | Placebo | LUM/IVA |
|---|---|---|
| Relative (Percent) Change From Baseline in Pulmonary Ventilation (VE) Versus Carbon Dioxide Production (VCO2) Slope at Week 24 | 2.0 (-0.7 to 4.6) | 3.0 (0.1 to 5.8) |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| percentage of predicted FEV1 | Placebo | LUM/IVA |
|---|---|---|
| Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Week 24 | -4.0 (-7.3 to -0.7) | -0.6 (-4.0 to 2.9) |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| percent change | Placebo | LUM/IVA |
|---|---|---|
| Relative (Percent) Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Week 24 | -5.4 (-10.3 to -0.5) | -1.8 (-6.9 to 3.2) |
BMI was defined as weight in kilograms (kg) divided by height in square meter (m\^2).
| kg/m^2 | Placebo | LUM/IVA |
|---|---|---|
| Absolute Change From Baseline in Body Mass Index (BMI) at Week 24 | 0.3 (0.0 to 0.6) | 0.5 (0.1 to 0.8) |
BMI was defined as weight in kg divided by height in m\^2.
| percent change | Placebo | LUM/IVA |
|---|---|---|
| Relative (Percent) Change From Baseline in BMI at Week 24 | 1.5 (0.0 to 3.1) | 2.5 (0.9 to 4.1) |
The CFQ-R assessed respiratory symptoms on a scale with scores ranging from 0 to 100; where higher scores indicated fewer symptoms and better health-related quality of life.
| units on a scale | Placebo | LUM/IVA |
|---|---|---|
| Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Week 24 | -6.1 (-11.7 to -0.5) | 0.1 (-5.9 to 6.1) |
The PHQ-8 is an eight item self-reported measure of depression. Each item is rated on a scale ranging from 0 (not at all) to 3 (nearly every day). Total score is the sum of individual eight items and ranges from 0 to 24, with higher scores indicating more severe depression symptoms. Total score of 0 to 5 indicates none to minimal depression, 6 to 10 indicates mild depression, 11 to 15 indicates moderate depression, 16 to 20 indicates moderately severe depression and 21 to 24 indicates severe depression.
| participants | Placebo | LUM/IVA |
|---|---|---|
| Baseline: None to minimal | 27 | 28 |
| Baseline: Mild | 8 | 5 |
| Baseline: Moderate | 0 | 1 |
| Baseline: Moderately severe | 1 | 0 |
| Baseline: Severe | 0 | 0 |
| Week 24: None to minimal | 23 | 24 |
| Week 24: Mild | 8 | 3 |
| Week 24: Moderate | 1 | 3 |
| Week 24: Moderately severe | 1 | 0 |
| Week 24: Severe | 0 | 0 |
The GAD-7 is a seven item, self-reported measurement of GAD severity. Each item is rated on a scale ranging from 0 (not at all) to 3 (nearly every day). Total score is the sum of individual seven items and ranges from 0 to 21, with higher scores indicating more severe anxiety symptoms. Total score of 0 to 5 indicates none to minimal anxiety, 6 to 10 indicates mild anxiety, 11 to 15 indicates moderate anxiety, 16 to 21 indicates severe anxiety.
| participants | Placebo | LUM/IVA |
|---|---|---|
| Baseline: None to minimal | 31 | 29 |
| Baseline: Mild | 5 | 5 |
| Baseline: Moderate | 0 | 0 |
| Baseline: Severe | 0 | 0 |
| Week 24: None to minimal | 26 | 26 |
| Week 24: Mild | 6 | 3 |
| Week 24: Moderate | 1 | 1 |
| Week 24: Severe | 0 | 0 |
Participants were provided with a wrist-worn actigraphy device which continuously collected data about daily physical activity counts.
| physical activity counts per day | Placebo | LUM/IVA |
|---|---|---|
| Absolute Change From Baseline in Daily Physical Activity Counts as Determined by Actigraphy at Week 24 | -23239 ± 73936.4 | -22409 ± 52450.1 |
Participants were provided with a wrist-worn actigraphy device which continuously collected data about daily physical activities.
| percent change | Placebo | LUM/IVA |
|---|---|---|
| Relative (Percent) Change From Baseline in Physical Activity as Determined by Actigraphy at Week 24 | -5 ± 26.9 | -7 ± 24.3 |
Participants were provided with a wrist-worn actigraphy device which continuously collected data about sleep duration and quality.
| hours | Placebo | LUM/IVA |
|---|---|---|
| Absolute Change From Baseline in Duration of Sleep Time at Week 24 | -0.4 ± 0.88 | 0.1 ± 0.74 |
Participants were provided with a wrist-worn actigraphy device which continuously collected data about sleep duration and quality.
| percent change | Placebo | LUM/IVA |
|---|---|---|
| Relative (Percent) Change From Baseline in Duration of Sleep Time at Week 24 | -5.7 ± 12.30 | 1.5 ± 9.79 |
Participants were provided with a wrist-worn actigraphy device which continuously collected data about daily activities and sleep duration and quality.
| hours | Placebo | LUM/IVA |
|---|---|---|
| Absolute Change From Baseline in Time Above Sedentary Duration at Week 24 | -0.7 ± 1.48 | -0.7 ± 2.09 |
Participants were provided with a wrist-worn actigraphy device which continuously collected data about daily activities and sleep duration and quality.
| percent change | Placebo | LUM/IVA |
|---|---|---|
| Relative (Percent) Change From Baseline in Time Above Sedentary Duration at Week 24 | 0.2 ± 64.76 | 2.3 ± 77.18 |
| participants | Placebo | LUM/IVA |
|---|---|---|
| Participants With AEs | 35 | 30 |
| Participants With SAEs | 9 | 15 |
Collected over Day 1 up to Week 28. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/36 (0%) | 9/36 (25%) | 34/36 (94.4%) |
| LUM/IVA | 0/34 (0%) | 15/34 (44.1%) | 28/34 (82.4%) |
| Event | Placebo | LUM/IVA |
|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 6/36 | 8/34 |
| Distal intestinal obstruction syndromeGastrointestinal disorders | 0/36 | 2/34 |
| Lower respiratory tract infection bacterialInfections and infestations | 0/36 | 1/34 |
| Inguinal herniaGastrointestinal disorders | 0/36 | 1/34 |
| TachycardiaCardiac disorders | 0/36 | 1/34 |
| FatigueGeneral disorders | 0/36 | 1/34 |
| Testicular torsionReproductive system and breast disorders | 0/36 | 1/34 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/36 | 1/34 |
| InfectionInfections and infestations | 0/36 | 1/34 |
| Cytomegalovirus infectionInfections and infestations | 1/36 | 0/34 |
| Event | Placebo | LUM/IVA |
|---|---|---|
| Respiration abnormalRespiratory, thoracic and mediastinal disorders | 9/36 | 5/34 |
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 6/36 | 8/34 |
| CoughRespiratory, thoracic and mediastinal disorders | 8/36 | 5/34 |
| Sputum increasedRespiratory, thoracic and mediastinal disorders | 5/36 | 2/34 |
| NauseaGastrointestinal disorders | 5/36 | 3/34 |
| Upper respiratory tract infectionInfections and infestations | 4/36 | 4/34 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 4/36 | 1/34 |
| NasopharyngitisInfections and infestations | 3/36 | 3/34 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 1/36 | 3/34 |
| Increased viscosity of bronchial secretionRespiratory, thoracic and mediastinal disorders | 0/36 | 3/34 |
| Age, Continuous(years) | Placebo | LUM/IVA | Total |
|---|---|---|---|
| Mean | 26.1 ± 10.58 | 24.9 ± 10.17 | 25.5 ± 10.33 |
| Sex: Female, Male(Participants) | Placebo | LUM/IVA | Total |
|---|---|---|---|
| Female | 18 | 13 | 31 |
| Male | 18 | 21 | 39 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | LUM/IVA | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 36 | 34 | 70 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | LUM/IVA | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 36 | 34 | 70 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2016 to primary completion in Sep 2017, 12 months.
Results were first posted in Jun 2019, 1 year 9 months after primary completion.
Of 30 phase 4 interventional studies under Cystic Fibrosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 48. This study's 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lumacaftor · Ivacaftor
Vertex Pharmaceuticals Incorporated →